Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides.

PubWeight™: 1.24‹?› | Rank: Top 10%

🔗 View Article (PMC 136904)

Published in J Virol on December 01, 2002

Authors

Jason J Coull1, Guocheng He, Christian Melander, Victor C Rucker, Peter B Dervan, David M Margolis

Author Affiliations

1: Division of Infectious Diseases, Department of Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA.

Associated clinical trials:

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (VORVAX) | NCT02707900

Articles citing this

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75

Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23

Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20

Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A (2003) 1.80

Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58

Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res (2003) 1.48

Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology (2006) 1.36

Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene (2004) 1.21

Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim Biophys Acta (2009) 1.01

Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. J Virol (2004) 1.01

Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J (2010) 0.98

Transcription through the HIV-1 nucleosomes: effects of the PBAF complex in Tat activated transcription. Virology (2010) 0.93

Latency reversal and viral clearance to cure HIV-1. Science (2016) 0.92

Programmable DNA-binding small molecules. Bioorg Med Chem (2013) 0.89

DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome (2004) 0.88

Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. J Virol (2005) 0.87

Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects. Crit Rev Oncog (2011) 0.86

Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. J Virol (2015) 0.85

Chromatin, non-coding RNAs, and the expression of HIV. Viruses (2013) 0.83

Complex of the herpes simplex virus type 1 origin binding protein UL9 with DNA as a platform for the design of a new type of antiviral drugs. J Biomol Struct Dyn (2013) 0.78

Articles cited by this

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12

Analysis of chromatin structure by in vivo formaldehyde cross-linking. Methods (1997) 7.08

Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J (1993) 3.95

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52

Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev (1997) 2.25

Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98

A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retroviruses (1990) 1.70

Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol (1997) 1.48

Activation of gene expression by small molecule transcription factors. Proc Natl Acad Sci U S A (2000) 1.40

Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappaB, and DNA by a designed DNA-binding ligand. J Biol Chem (1999) 1.16

Protein-DNA interactions within DNase I-hypersensitive sites located downstream of the HIV-1 promoter. J Biol Chem (1994) 1.16

Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides. Biochemistry (1999) 1.04

Cyclic polyamides for recognition in the minor groove of DNA. Proc Natl Acad Sci U S A (1995) 1.00

Inhibition of major-groove-binding proteins by pyrrole-imidazole polyamides with an Arg-Pro-Arg positive patch. Chem Biol (1998) 0.88

Articles by these authors

The challenge of finding a cure for HIV infection. Science (2009) 8.41

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17

Defining the sequence-recognition profile of DNA-binding molecules. Proc Natl Acad Sci U S A (2006) 2.97

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80

Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS (2009) 2.28

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27

Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25

c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24

Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09

Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis (2007) 2.05

Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97

Arresting cancer proliferation by small-molecule gene regulation. Chem Biol (2004) 1.90

Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Res (2004) 1.84

Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc (2008) 1.84

Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84

Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol (2003) 1.81

Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proc Natl Acad Sci U S A (2003) 1.80

DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia. Proc Natl Acad Sci U S A (2006) 1.70

Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis (2008) 1.66

Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob Agents Chemother (2010) 1.64

Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis (2004) 1.64

Crystal structures of nucleosome core particles in complex with minor groove DNA-binding ligands. J Mol Biol (2003) 1.63

Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol (2011) 1.61

Allosteric modulation of DNA by small molecules. Proc Natl Acad Sci U S A (2009) 1.61

Completion of a Programmable DNA-Binding Small Molecule Library. Tetrahedron (2007) 1.58

Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis (2006) 1.57

Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56

Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Res (2006) 1.55

Cellular uptake of N-methylpyrrole/N-methylimidazole polyamide-dye conjugates. Bioorg Med Chem (2002) 1.52

Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol (2011) 1.52

Small molecule control of bacterial biofilms. Org Biomol Chem (2012) 1.51

Solid-phase synthesis of DNA binding polyamides on oxime resin. Bioorg Med Chem (2002) 1.45

Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol (2009) 1.41

Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. HIV Clin Trials (2003) 1.41

No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.39

Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proc Natl Acad Sci U S A (2009) 1.38

Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38

Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37

Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc Natl Acad Sci U S A (2011) 1.36

Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis (2008) 1.32

Quantitative microarray profiling of DNA-binding molecules. J Am Chem Soc (2007) 1.30

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis (2009) 1.28

Molecular recognition of the nucleosomal "supergroove". Proc Natl Acad Sci U S A (2004) 1.25

Controlling bacterial biofilms. Chembiochem (2009) 1.24

Next generation hairpin polyamides with (R)-3,4-diaminobutyric acid turn unit. J Am Chem Soc (2008) 1.23

Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J Am Chem Soc (2009) 1.21

Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy (2004) 1.19

Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol (2013) 1.18

Synthesis and screening of an oroidin library against Pseudomonas aeruginosa biofilms. Chembiochem (2008) 1.15

Structural basis for cyclic Py-Im polyamide allosteric inhibition of nuclear receptor binding. J Am Chem Soc (2010) 1.15

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA (2006) 1.14

Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus. Angew Chem Int Ed Engl (2012) 1.14

Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retroviruses (2012) 1.14

Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2013) 1.13

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 1.13

The regulation of HIV-1 gene expression: the emerging role of chromatin. DNA Cell Biol (2002) 1.13

Inhibition of Pseudomonas aeruginosa biofilm formation with Bromoageliferin analogues. J Am Chem Soc (2007) 1.13

Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med (2009) 1.13

Sequence specific fluorescence detection of double strand DNA. J Am Chem Soc (2003) 1.11

A 2-aminobenzimidazole that inhibits and disperses gram-positive biofilms through a zinc-dependent mechanism. J Am Chem Soc (2009) 1.11

Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse. J Virol (2011) 1.11

Blocking transcription through a nucleosome with synthetic DNA ligands. J Mol Biol (2002) 1.11

Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues. Org Biomol Chem (2008) 1.10

Shape selective recognition of T.A base pairs by hairpin polyamides containing N-terminal 3-methoxy (and 3-chloro) thiophene residues. Bioorg Med Chem (2003) 1.10

Small molecule transcription factor mimic. J Am Chem Soc (2004) 1.10

Synthesis and antibiofilm activity of a second-generation reverse-amide oroidin library: a structure-activity relationship study. Chemistry (2008) 1.09

Design of artificial transcriptional activators with rigid poly-L-proline linkers. J Am Chem Soc (2002) 1.09

Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing bacterial biofilms across order, class, and phylum. Angew Chem Int Ed Engl (2008) 1.09

Role of mismatch repair enzymes in GAA·TTC triplet-repeat expansion in Friedreich ataxia induced pluripotent stem cells. J Biol Chem (2012) 1.09

A new small molecule specifically inhibits the cariogenic bacterium Streptococcus mutans in multispecies biofilms. Antimicrob Agents Chemother (2011) 1.08

Quantitating the concentration of Py-Im polyamide-fluorescein conjugates in live cells. Bioorg Med Chem Lett (2008) 1.08

In vivo imaging of pyrrole-imidazole polyamides with positron emission tomography. Proc Natl Acad Sci U S A (2008) 1.07

DNA-templated dimerization of hairpin polyamides. J Am Chem Soc (2003) 1.07

Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation. Retrovirology (2013) 1.06

Programmable oligomers for minor groove DNA recognition. J Am Chem Soc (2006) 1.06

Targeted chemical wedges reveal the role of allosteric DNA modulation in protein-DNA assembly. ACS Chem Biol (2008) 1.06

Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr (2004) 1.05

Words matter: Discussing research towards an HIV cure in research and clinical contexts. J Acquir Immune Defic Syndr (2014) 1.04

Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A (2012) 1.04

Small molecule suppression of carbapenem resistance in NDM-1 producing Klebsiella pneumoniae. ACS Med Chem Lett (2012) 1.04